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RECENT CONCERNS
It is by now a truism in the lay press that “antidepressants are no more effective than sugar pills.”1
Although the best available evidence does not support this conclusion,2–4 public skepticism regarding
the efficacy of antidepressants is understandable, given several recent developments. Furthermore, con-
cerns over possible adverse effects of antidepressants, including increased risk of “suicidality” in youn-
ger populations, have continued to darken the public's perception of these agents.
Recently, these controversies came to a head after a reanalysis5 of SmithKline Beecham's random-
ized, double-blind Study 329, comparing paroxetine and imipramine with placebo in adolescents with
unipolar major depression. The reanalysis, which used previously confidential documents, concluded
that—contrary to the original findings—“…neither paroxetine nor high dose imipramine showed effi-
cacy for major depression in adolescents, and there was an increase in harms with both drugs.”5 The
“harms” included clinically significant increases in suicidal ideation and behavior. In an editorial accom-
panying the BMJ paper, Dr David Henry commented, “It's not clear whether it was deliberate or acciden-
tal, but [the original report] wrongly gave the impression that an antidepressant drug was effective and
safe in children and adolescents.”6
Furthermore, the issue of “ghost writing” of antidepressant studies and/or heavy involvement of
pharmaceutical industry authors has received renewed scrutiny. One recent review concluded that “There
is a massive production of meta-analyses of antidepressants for depression authored by or linked to the
industry, and they almost never report any caveats about antidepressants in their abstracts.”7 In addition,
the issue of publication bias in the antidepressant literature remains a thorny problem. Thus, Turner et al8
compared 74 Food andDrugAdministration–registered antidepressant trials submitted for regulatory ap-
proval (for 12 antidepressants involving 12,564 patients) with the published literature. They found evi-
dence of the “file drawer effect,” that is, publication bias in favor of positive studies. In the backdrop of
these findings are some influential meta-analyses suggesting that the efficacy of antidepressants for ma-
jor depression is exaggerated and/or limited to severe depression.9,10
Taken in toto, these revelations can only deepen the public's concern—if not cynicism—regarding
both the validity of antidepressant studies and possible harms from these agents. Yet, amidst the flurry of
media reports on Study 329, the many nuances of antidepressant research were often obscured, and the
“bigger picture” was generally missed. For despite the apparent failure of Study 329, the preponderance
of research still supports modest-to-moderate efficacy—and overall safety—for several commonly
used antidepressants.2–4,11,12
BROADER CONCERNS AND COMPLEXITIES
That said, there are still many theoretical and practical problems in the way antidepressant studies
are carried out and interpreted; moreover, questions remain as to the degree of major depression (mild,
moderate, or severe) for which antidepressants are effective. Underlying these issues are even broader
concerns, such as the marked heterogeneity in the Diagnostic and Statistical Manual of Mental Disor-
ders, Fifth Edition (DSM-V) construct of “major depressive disorder” (MDD),13 the dissimilarity be-
tween research subjects in antidepressant registration trials and “real-world” patients,14 problems and
limitations inherent in all meta-analyses,15 and rising rates of the placebo response in studies of depres-
sion conducted in the past few decades.16
To complicate matters further: the outcome of antidepressant studies may depend critically on what
“level” of data is assessed. For example, based on the Hamilton Depression Scale (HAMD), Gibbons
et al11 (2012) have pointed to the difference between average study-level initial severity and antidepres-
sant response, on the one hand, and patient-level data, on the other. These researchers argue that “…rel-
atively small overall mean differences can translate into relatively large patient-level differences in
clinically interpretable and meaningful endpoints such as response and remission.”
Thus, Gibbons et al11 recently examined the short-term efficacy of antidepressants for treating ma-
jor depression in youth, adults, and geriatric populations. The authors carried out a reanalysis of allpstate Medical University, Syracuse, NY; and Tufts University School of Medicine, Boston, MA.
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6 weeks of treatment of MDD. Data were derived from both pub-
lished and unpublished studies, conducted by the manufacturers
of fluoxetine and venlafaxine. These included 20 randomized,
placebo-controlled trials of fluoxetine (12 adult, 4 geriatric, and
4 youth) and 21 adult trials of venlafaxine. Complete longitudinal
patient records were obtained, allowing the authors to examine as-
sociations between treatment response and baseline severity mea-
sured at the patient level. The study found that patients in all age
and drug groups had significantly greater improvement relative to
placebo controls, and baseline severity of depression did not affect
symptom reduction. The authors concluded that “…The results do
not support previous findings that antidepressants show little ben-
efit except for severe depression. The antidepressants fluoxetine
and venlafaxine are efficacious for major depression, in all age
groups although more so in youth and adults compared with geri-
atric patients. Baseline severity was not significantly related to de-
gree of treatment advantage over placebo.”11
In a companion article, Gibbons et al12 examined suicidal
thoughts and behavior in the same set of randomized, placebo-
controlled studies of fluoxetine and venlafaxine and again used
longitudinal patient-level data. The suicide items from the Chil-
dren's Depression Rating Scale-Revised and the HAMD, as well
as adverse event reports of suicide attempts and suicide during ac-
tive treatment, were analyzed in 9185 patients. The study found
that “Fluoxetine and venlafaxine decreased suicidal thoughts
and behavior for adult and geriatric patients. This protective effect
is mediated by decreases in depressive symptoms with treatment.
For youths, no significant effects of treatment on suicidal thoughts
and behavior were found, although depression responded to treat-
ment. No evidence of increased suicide risk was observed in youths
receiving active medication.”12
The use of longitudinal patient-level data is a genuine strength
of the Gibbons et al studies. However, both studies by Gibbons et al
came in for withering criticism in subsequent letters to the edi-
tor,17,18 followed by vigorous rejoinders by Gibbons et al. A com-
plete discussion of these critiques is beyond the scope of this
editorial, but a few points are worth noting. For example, inclu-
sion of the LYAQ fluoxetine trial in the Gibbons et al data—which
looked at subjects with comorbid attention-deficit/hyperactivity
disorder and depression—may have distorted the aggregate anal-
ysis because 19% of LYAQ subjects did not have depression.18
There is also controversy over the use of rating scales (such as
the Children's Depression Rating Scale-Revised) as a measure
of suicidality, as opposed to spontaneous reports of suicidal thoughts
or behaviors.
OTHER STUDIES SUPPORTING
ANTIDEPRESSANT EFFICACY AND SAFETY
While acknowledging shortcomings in the 2 studies by
Gibbons et al, it is important to note that the results of these
studies are largely consistent with several other recent analyses.
For example, Vöhringer and Ghaemi3 conducted their own re-
analysis of the US Food and Drug Administration database MDD
studies specifically analyzed by Kirsch et al. The reanalysis cor-
rected for a statistical “floor effect” so that relative (instead of abso-
lute) effect size differences were calculated; that is, drug-placebo
differences were adjusted for baseline severity of illness. This led
to an increase in nonstandardized effect size from 0.32 (as per
Kirsch et al) to 0.40. Contrary to Kirsch et al (2008)—who found
antidepressants effective only in the most severely depressed
patients—the Vöhringer and Ghaemi3 reanalysis found that “…an-
tidepressants are effective in acute depressive episodes that are
moderate to severe…,” although not in mild depressive episodes.2 www.psychopharmacology.com
Copyright © 2015 Wolters Kluwer Health, Inc. UnautIn partial contrast, Stewart et al19 analyzed 6 placebo-
controlled antidepressant studies of patients with nonsevere MDD
(HAMD score < 23) and found that “mild-moderate MDD can ben-
efit from antidepressants,” with the number needed to treat in the
range of 3 to 8 (number needed to treat < 10 is considered clinically
significant). It seems fair to conclude that the effectiveness of antide-
pressants for “mild” cases of major depression is still unclear—but
there is little doubt that antidepressants are effective acutely in
moderate-to-severe major depression.
Recently, Thorlund et al20 conducted ameta-analysis of selec-
tive serotonin reuptake inhibitors and serotonin-norepinephrine re-
uptake inhibitors in adults 60 years and older, using data from 15
randomized, controlled trials.With respect to achieving a partial re-
sponse, the authors found “…clear evidence of the effectiveness of
sertraline, paroxetine, and duloxetine” in this study population.
Furthermore, although the issue of “suicidality” in younger
populations treated with antidepressants remains controversial, 2
recent analyses suggest a “neutral” effect of selective serotonin re-
uptake inhibitors on suicide risk in children and adolescents.21,22
Thus, Ghaemi21 concluded that “SRIs increase suicide risk in
1% of children, and lead to completed suicide in about 1 in 500,
which is the same as their prevention rate. Their overall effect is
probably neutral when benefits are weighed against harms.”
Similarly, Carroll22 found “…evidence of equipoise between the
therapeutic outcome of preventing suicide and any potential drug-
related provocation of suicide among adolescents treated for
MDD with fluoxetine.”
Notably, a recent consensus conference on antidepressant
safety highlighted the marked ambiguity in the term “suicidality”—
which can mean anything from suicidal ideation to a completed
suicide. The consensus authors pointedly observed that “…no
deaths from suicide were reported in any of the 24 pediatric [an-
tidepressant] trials involving 4,582 patients.”23 Indeed, suicidal
ideation per se is a poor predictor of completed suicide,24 which
remains a poorly studied phenomenon; for example, randomized
controlled studies routinely exclude subjects at high risk for sui-
cide. Finally, it is important to note that, in adult populations,
there are no controlled studies demonstrating increased rates of
completed suicides associated with newer antidepressants.12ARE WE HAMSTRUNG BY THE HAMD?
The HAMD (or HDRS) is so widely used in antidepressant
research; it has become nearly synonymous with measures of an-
tidepressant efficacy. (It has sometimes been said that most antide-
pressant studies are illustrations of how strongly antidepressants
affect the HAMD, more so than how well they treat depression.)
However, the HAMD itself is subject to variability, depending
on the level of experience of the rater: for example, poorly trained
raters tend to produce results that diminish the effect of the antide-
pressant.25 Furthermore, as Bagby et al26 (2004) have observed
that “…many [HAMD] scale items are poor contributors to the
measurement of depression severity; others have poor inter-rater
and retest reliability.”
Indeed, much may depend on which version of the HAMD
(HAMD17, HAMD21, HAMD24, etc) or which HAMD item
cluster is used. In a key study using the HAMD6, Bech4 (2010)
reported on a “reallocation” of HAMD items, focusing on the 6
items measuring severity of clinical depression—depressedmood,
guilt, work and interests, tiredness, anxiety, and psychomotor
retardation. For second-generation antidepressants in placebo-
controlled trials, application of the HAMD6 resulted in clini-
cally significant effect sizes of 0.40 or greater.4
That said, the HAMD is not necessarily the last word in mea-
suring antidepressant response. Indeed, it is rare to find studies of© 2015 Wolters Kluwer Health, Inc. All rights reserved.
horized reproduction of this article is prohibited.
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study subjects, although arguably, it is precisely this factor that
matters most to our patients. Two notable exceptions to the
“HAMDworld view” are the studies by Skevington and Wright27
(2001) and Berlim et al28 (2007). The Skevington and Wright
study examined general practice patientswithmoderate depression
(n = 106) by DSM-IV criteria. Subjects completed the 100-item
WorldHealthOrganizationQuality of LifeAssessment (WHOQOL)
and the Beck Depression Inventory, before the start of antidepres-
sant treatment and 6 weeks afterward. Depression decreased sig-
nificantly for 2 months, with 74% reported feeling better. The
100-item World Health Organization Quality of Life Assessment
scores increased in 24 of the 25 facets, “…demonstrating that
QOL improves significantly in the 8 weeks following the start
of antidepressant treatment…” and that “…antidepressants signif-
icantly and comprehensively improve QOL” in this sample.
In a Brazilian study by Berlim et al,28 73 patients presenting
with a severe episode of major depression were assessed by the
WHOQOLBREF (26 items derived from the 100-itemWHOQOL)
and the Beck Depression Inventory at the start of antidepressant
treatment and again after amean of 12weeks. The depressed patients'
QOL scores significantly improved in all the assessed domains (ie,
physical health, psychological, social relations, environmental, and
overall QOL) during the study period. Moreover, there was signifi-
cant improvement in depressive symptoms between test and retest
(effect sizes ranged from 0.49 to 1.08; ie, medium-to-large effects).
Although these are relatively small, uncontrolled studies, they
suggest that QOL may be enhanced by antidepressant treatment—
perhaps a more important clinical measure than HAMD scores.AQ3OTHER PROBLEMS WITH
ANTIDEPRESSANT STUDIES
As noted previously,13 the DSM-IV/V construct of MDD is
extraordinarily elastic and heterogeneous. Moreover, DSM-V field
trials have revealed “questionable” reliability (kappa = 0.20–0.39)
for the diagnosis of MDD.29 Given that a patient with MDD may
have had the requisite symptoms for as little as 2 weeks, or as long
as 2 years; be able to work or not be able; and so forth, it is almost
inevitable that the DSM criteria will capture a wide range of MDD
types and severity.Most randomized, controlled studies ofMDDdo
not attempt to distinguish betweenMDD symptoms present for, say,
2 versus 12 months. Nor do most studies look specifically at sub-
jects with MDD who meet criteria for the specifier, “with melan-
cholic features”—a more serious form of MDD that is poorly
responsive to placebo, compared with nonmelancholic MDD.30
Indeed, some have argued that “melancholia” (a related con-
struct) ought to be considered a distinct mood disorder.31 It seems
axiomatic that the presence or absence of melancholic features
will result in discrepant findings, with respect to drug versus
placebo differences.
Finally, we have yet to solve the puzzle of increasing placebo
response rates in more recent studies of major depression. (Con-
trary to much misrepresentation in the lay press, the placebo con-
dition is much more than “a sugar pill” and usually includes 8 or
more hours of weekly, supportive contact with professional staff.32)
As 1 review noted, “Since the response to placebo is variable, often
substantial, and increasing, it is not surprising that in many random-
ized controlled trials the response associated with placebo is similar
to that associated with an established antidepressant.”16 One possi-
ble factor in this trend is the changing demographics of research
subjects assigned to the placebo condition. Bridge et al33 (2009)
hypothesized that, in some multisite studies of MDD, subjects
with less severe depressive illness may have been recruited—which© 2015 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2015 Wolters Kluwer Health, Inc. Unauwould likely inflate placebo response rates and diminish drug-
placebo differences.
CONCLUSIONS
The preponderance of data from randomized, controlled
studies suggests that modern antidepressants are modestly effec-
tive and generally safe, in the acute treatment of major depression.
Notwithstanding these upbeat conclusions, many problems con-
tinue to complicate the research literature, including but not lim-
ited to publication bias, rising rates of the placebo response,
marked heterogeneity in the construct of “MDD,” and the exclu-
sion of “real-world” patients (eg, those with comorbidities or high
suicide risk) from randomized, controlled studies.
Going forward, we need to increase “transparency” in publi-
cation, by, for example, making raw study data available to journal
reviewers.34 We need to reexamine our entry criteria for antide-
pressant trials so that study subjects more closely resemble those
we treat in clinical practice. We need to refine our recruitment
methods so that highly placebo-responsive subjects are not in-
cluded in randomized controlled studies. We must also address
the marked heterogeneity in the DSM-V construct of MDD, via
more fine-grained examination of MDD subgroups, for example,
patients with chronic and melancholic major depressive episodes.
Furthermore, with respect to antidepressant efficacy, we must move
beyond the HAMD toward broader assessments of “QOL.” Finally,
we need to intensify our outreach and education efforts so that the
important role of antidepressant treatment is better appreciated by
the general public.
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